Physician profile
William Charles Ware
NPI 1497716849
$25,703.43
in general payments reported to CMS, 2019-2025
62 companies · $4,230 in 2025
The $4,230 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,382 · 2020: $4,082 · 2021: $3,172 · 2022: $3,172 · 2023: $3,664 · 2024: $4,002 · 2025: $4,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,895.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,083.17 | 2019-2025 | |
| Novo Nordisk INC | $2,559.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,251.09 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,964.66 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,763.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,516.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,213.18 | 2019-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $981.94 | 2019-2025 | Xifaxan, Cycloset |
| Sanofi-Aventis U.S. LLC | $974.21 | 2019-2025 | |
| Harmony Biosciences LLC | $875.57 | 2022-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $823.71 | 2019-2025 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $623.65 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $538.73 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $537.52 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $519.77 | 2019-2024 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.